Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from ...

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...

Zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic gastroesophageal adenocarcinoma.

Dr. Elena Elimova discusses how Ziihera-based therapy may change treatment for HER2+ locally advanced or metastatic ...

Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline ...

Florida Cancer Specialists & Research Institute, LLC (FCS) advances gastrointestinal cancer treatment through participation ...

Breast cancer can spread—or metastasize—to many different parts of the body, but it's not well understood why tumors grow better in some organs than others.

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall ...

The global cancer drugs market is surging toward $594.3 billion by 2035 as high-tech immunotherapies begin to replace ...

HUTCHMED has commenced the Phase III stage of its ongoing Phase II/III clinical trial assessing the combination of ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...